Key Highlights
- EMA endorsement allows commercially manufactured GP2 to be used in FLAMINGO-01 across roughly 170‑180 European locations.
- Production capacity reaches approximately 200,000 doses from the first three active‑ingredient lots.
- Over 1,300 patients have been screened in the Phase III FLAMINGO-01 trial, with recurrence rates cut by up to 80%.
- Patient informed consent completion stands at approximately 70-80%, and five‑year follow‑up shows an 80% survival metric.
Greenwich LifeSciences (NASDAQ: GLSI) reported that the European Medicines Agency has granted approval for its GP2 immunotherapy in the FLAMINGO-01 Phase III trial. The decision opens the pathway for up to approximately 200,000 doses to be administered across an expanded network of 170‑180 European sites, widening the therapeutic options for breast cancer recurrence prevention.
What Happened
The EMA review concluded that commercially manufactured GP2 can be employed in the FLAMINGO-01 study, which began enrolling patients in 2023. First commercial lots of the active ingredient were produced in 2023, delivering about 200,000 doses, while the inaugural vial‑filling batch was completed in 2024. The trial has screened more than 1,300 patients to date, with a non‑HLA‑A02 arm fully enrolled at 250 participants and a Phase IIb cohort of roughly 50 treated patients.
Market Impact
The approval is poised to stimulate demand for specialized biologic manufacturing capacity and could lift activity in the European oncology market. With the drug now eligible for use at an estimated 170‑180 sites, suppliers of vials, cold‑chain logistics, and specialty pharmacies are expected to see incremental volumes. The broader adoption may also prompt investors to reconsider exposure to companies operating in the breast‑cancer immunotherapy space, as the therapeutic effect includes a reduction in recurrence of up to 80% and a five‑year follow‑up survival rate of 80%.
What's Next
Greenwich plans to pursue separate regulatory clearances in the United Kingdom and Canada, while its U.S. Approval was secured earlier in 2026, covering 40‑50 sites. The company aims to maintain a screening rate of approximately 800 patients per year as the trial progresses toward completion. Additional data on response rates, ranging between 20‑50%, will be disclosed as the study reaches its primary endpoint later this year.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...